NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories Holdings, Ltd. (collectively, "Forest") announced today that they have entered into a settlement agreement with Actavis, Inc. and related companies and subsidiaries thereof, in patent infringement litigation brought by Forest in response to Actavis’s abbreviated new drug application ("ANDA") seeking approval to market generic versions of Forest's BYSTOLIC® (nebivolol) tablets. This settlement agreement is with the last of the remaining defendants in this patent infringement litigation.
Help employers find you! Check out all the jobs and post your resume.
